Summary of Eledon Pharmaceuticals Conference Call Company Overview - **Company**: Eledon Pharmaceuticals (NasdaqCM:ELDN) - **Focus**: Development of immunosuppressive therapies for organ transplantation, particularly kidney and islet cell transplants Key Points from the Conference Call Phase 2 BESTOW Study Results - The Phase 2 BESTOW study showed promising outcomes, achieving a non-inferiority margin for a composite endpoint, which is crucial for Phase 3 approval [1] - Although the primary endpoint of kidney function was not met, the data indicated that the treatment outperformed standard care in various aspects [1][2] - Safety profile was significantly better, with a ninefold reduction in tremors and a sevenfold reduction in infection rates compared to standard care [3] Market Perception and Data Interpretation - The market may have underestimated the implications of missing the kidney function endpoint, as the approvable endpoint for kidney transplant studies is a composite endpoint unrelated to kidney function [4] - Acute rejection rates were higher in the tegoprubart arm (20%) compared to the tacrolimus arm (14%), but all rejections in the tegoprubart group occurred within the first six months [5] Phase 3 Study Planning - Eledon plans to request an end-of-phase 2 meeting with the FDA in late Q1 or early Q2 2026 to discuss the Phase 3 study design [10] - The primary endpoint for the Phase 3 study will focus on patient and graft survival, with a non-inferiority design [15][17] Long-term Data and Quality of Life Measures - Long-term follow-up data from a Phase 1b study showed no acute rejections and 100% survival, indicating potential for better long-term outcomes compared to standard care [7][8] - The Phase 3 study will include patient-reported outcomes to assess quality of life and toxicities associated with standard care [21] Commercial Opportunity - Eledon believes tegoprubart could become the new standard of care in transplantation, with potential applications in both allotransplant and xenotransplant settings [28] - The company aims to address the limitations of current therapies and believes that the infrastructure for drug administration has improved since previous launches [27] Islet Cell Program - The islet cell transplant program has shown promising results, with several patients achieving independence from insulin [31][32] - Eledon plans to transition this program into a sponsored study, with an IND filing expected by the end of 2026 [33][35] Xenotransplantation Developments - Eledon is collaborating on xenotransplantation studies, showing significant progress with genetically modified pig organs [41][42] - The company plans to supply tegoprubart as part of the immunosuppressive regimen for xenotransplantation, leveraging safety and efficacy data from ongoing studies [43] Financial Position and Future Milestones - Eledon has sufficient cash to fund operations through Q2 2027, with key milestones including the opening of INDs for kidney and islet cell transplant studies [50][51] - The company is committed to supporting ongoing research in xenotransplantation and other transplant-related studies [52] Additional Insights - The discussion highlighted the importance of managing immunosuppression protocols in clinical trials to ensure balanced treatment across study arms [23][24] - The potential for xenotransplantation to alleviate organ shortages presents a significant commercial opportunity, as many patients remain on waiting lists without receiving transplants [44]

Summary of Eledon Pharmaceuticals (ELDN) Conference Call Company Overview - **Company**: Eledon Pharmaceuticals - **Focus**: Development of tegoprubart for kidney transplant rejection prevention Industry Context - **Industry**: Biotech, specifically in transplant medicine - **Current Standard of Care**: Calcineurin inhibitors, primarily tacrolimus, which has been in use since 1994 Key Points and Arguments Unmet Need in Kidney Transplantation - Tacrolimus has significant limitations including nephrotoxicity, hypertension, and beta cell toxicity leading to hyperglycemia and insulin-dependent diabetes [4][5] - The average survival of transplanted kidneys is between 10 to 15 years, with patients often requiring multiple transplants due to organ scarcity [5][6] Tegoprubart Development - Tegoprubart is being evaluated in Phase 1B and Phase 2 trials as an alternative to tacrolimus [3] - The goal is to improve patient quality of life and organ survival by reducing adverse effects associated with tacrolimus [5] Clinical Trial Design and Endpoints - **Phase 1B Study**: Focused on safety and tolerability, with endpoints including rejection rates and kidney function measured by eGFR [14][15] - **Phase 2 Study (BESTOW)**: Designed to demonstrate superiority over tacrolimus, with a primary endpoint of kidney function at 12 months, aiming for an eight-point difference in eGFR [15][34] iBOX Score as a New Endpoint - iBOX is a composite endpoint that includes eGFR, DSA, proteinuria, and time since transplant, which is a better predictor of long-term graft survival than traditional biopsy-proven rejection [7][19] - Eledon reported an iBOX score of negative 4.1 in the on-treatment group, significantly better than the average CNI iBOX score of negative 2.9 [18][22] Rejection Rates and Safety Profile - The rejection rate in the Phase 1B study was reported at 18%, comparable to BALADA sub-studies in the low 20s, while standard care is in the high single digits [23][24] - The safety profile showed no significant adverse events typically associated with tacrolimus, such as graft loss or sepsis [45] Market Opportunity - Approximately 48,000 transplants occur annually in the U.S., with nearly 30,000 being kidney transplants [48] - The U.S. transplant immunosuppressant market is substantial, with tacrolimus generating nearly $1.5 billion in annual revenues [48] Future Expectations - Eledon anticipates presenting data from the Phase 2 study in Q4 and expects to launch Phase 3 trials in the second half of the following year [54][58] - The company is also exploring islet cell transplantation and xenotransplantation, with ongoing studies expected to yield more data [58] Additional Important Insights - The FDA is considering new approval endpoints that may allow for superiority claims based on iBOX scores [11][12] - The concentrated nature of the transplant market, with only 40 centers performing half of the transplants, presents a unique opportunity for Eledon to leverage existing relationships [48][51] This summary encapsulates the critical insights from the conference call, highlighting Eledon's strategic focus on addressing unmet needs in kidney transplantation through innovative therapies and the potential market impact.